wugen
media
BIOSPACE article, july 2019
WUGEN attacks gaps in car-t therapy
ST. LOUIS, APR. 30, 2019
Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion
ST. LOUIS, mar. 26, 2019
WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development
ST. LOUIS, feb. 20, 2019
WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR
Presentations feature new preclinical data on WUGEN’s core fratricide-resistant CAR-T therapy platform targeting T-cell malignancies.
ST. LOUIS, DEC. 3, 2018
WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting
Platform demonstrates curative treatment of T-cell cancers using fratricide-resistant UCART in preclinical model.
ST. LOUIS, Nov. 13, 2018
WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis
ST. LOUIS, Nov. 1, 2018
WUGEN Announces Presentations at American Society of Hematology Annual Meeting
Company presents first clinically viable therapy to address a cancer with no effective targeted treatment